WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. CINC today announced that company management will present at the following investor conferences in November:
The CinCor management team will participate in one-on-one investor meetings during these events. Investors interested in meeting with CinCor at the conference should contact their Piper Sandler or Evercore ISI representative. An archived replay of the presentations will be available for 90 days at CinCor.com/events.
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.
|Michael Kalb||Bob Yedid|
|CinCor Pharma, Inc.||LifeSci Advisors|
|EVP and CFO||ir@CinCor.com|
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article